

Supplementary Data

**SUPPLEMENTARY TABLE S1. ACTG A5269 BASELINE
GENE EXPRESSION BY TREATMENT RESPONSE**

<i>Median gene expression by treatment response</i>			
<i>Gene</i>	<i>SVR</i>	<i>NR</i>	<i>p*</i>
<i>IFIT2</i>	0.021	0.012	0.121
<i>STAT1</i>	0.345	0.286	0.251
<i>IFIT3</i>	0.019	0.013	0.258
<i>ISG15</i>	0.046	0.030	0.282
<i>OAS1</i>	0.034	0.025	0.290
<i>OASL</i>	0.023	0.015	0.290
<i>IFIT1</i>	0.023	0.010	0.299
<i>TRIM5</i>	0.021	0.018	0.307
<i>IFITM3</i>	0.177	0.198	0.343
<i>IFNA2</i>	0.004	0.003	0.371
<i>IFI27</i>	0.003	0.001	0.395
<i>PLSCR1</i>	0.009	0.010	0.499
<i>LY6E</i>	0.193	0.176	0.510
<i>RARRES3</i>	0.132	0.114	0.522
<i>STAT2</i>	0.092	0.087	0.595
<i>IRF9</i>	0.042	0.038	0.620
<i>IFITM2</i>	0.416	0.400	0.672
<i>IRF1</i>	0.559	0.552	0.698
<i>OAS2</i>	0.144	0.129	0.739
<i>IFNB1</i>	0.001	0.001	0.766
<i>STAT6</i>	0.322	0.317	0.790
<i>TRIM14</i>	0.052	0.042	0.861
<i>MX1</i>	0.050	0.061	0.907
<i>MX2</i>	0.127	0.141	0.921
<i>IRF7</i>	0.106	0.114	0.935
<i>IFI44</i>	0.029	0.028	0.950
<i>SP110</i>	0.080	0.076	0.964
<i>TYK2</i>	0.067	0.063	1.000

All genes analyzed were similarly expressed between SVR and NR before initiation of therapy. The primers are all commercially available and were obtained from Applied Biosystems (www.thermofisher.com/us/en/home/brands/applied-biosystems.html) and will be made available upon request.

None met the predetermined FDR at 10% using the Benjamini-Hochberg procedure.

*Exact Wilcoxon test.

FDR, false discovery rate; NR, nonresponder; SVR, sustained virologic response.